Antivirus therapy in the complex treatment of preneopiastic cervix uteri diseases with chronicle HPV-infection

Abstract


This research devoted to determination of the clinical efficiency of preparation allokin-alpha and panavir in the therapy of cervix uteri diseases associated with human papillomavirus (HPV).The article presents data of the complex examination of 158 patients with chronicle HPV-infection. Condition of immune suppression of 14 patients with precancer of cervix uteri and chronicle HPV-infection was studied in dynamics in complex treatment with allokin-alpha. Level of the expression of transforming growth factor (31 (TGF-(31) gene and transcription factor FOXP3 gene were determined for estimation of function condition of regulating lymphocyte (Treg). Clinical efficiency of complex treatment HPV-infection associated with different cervix uteri diseases using allokin-alpha and panavir was 91,9% and 84,7%. It was found that patients with chronicle HPV- infection characterized with certain level of immune suppression which doesn't allow effective suppress of the reproduction of the virus and manifests in increased expression of molecular markers of regulating lymphocyte-suppressors. In complex therapy patients with precancer of cervix uteri and HPV-infection using preparation allokin-alpha courses decrease of expression of inhibition cytokineTGF-(31 gene and FOXP3 gene and that performed the real opportunity using allokin-alpha for immune modulating on the level of regulating lymphocyte for increasing antivirus immune reply. Using antiviral therapy permits to prevent recurrent of papillomavirus infection of cervix uteri.

P I Kovchur

Petrozavodsk State University; Russian Academy of Sciences Karelian Research Centre Institute of Biology, Petrozavodsk

Email: pkovchur@mail.ru

I E Bahlaev

Petrozavodsk State University; Russian Academy of Sciences Karelian Research Centre Institute of Biology, Petrozavodsk

E K Oleinik

Petrozavodsk State University; Russian Academy of Sciences Karelian Research Centre Institute of Biology, Petrozavodsk

V M Oleinik

Petrozavodsk State University; Russian Academy of Sciences Karelian Research Centre Institute of Biology, Petrozavodsk

A V Churov

Petrozavodsk State University; Russian Academy of Sciences Karelian Research Centre Institute of Biology, Petrozavodsk

  1. Аксель Е.М. Статистика злокачественных новообразований женских половых органов // Опухоли женской репродуктивной системы. 2009. № 1-2. С. 76-78.
  2. Ашрафян Л.А., Киселев В.И. Современные возможности профилактики и ранней диагностики предрака и рака репродуктивных органов // Акушерство и гинекология. 2009. № 4. С. 24-29.
  3. Бахлаев И.Е., Ковчур П.И. Профилактика рака шейки матки в условиях женской консультации // Опухоли женской репродуктивной системы. 2009. № 3^1. С. 94-98.
  4. Голованова В.А., Новик В.И., Гуркин Ю.А. Частота и факторы риска папилломавирусной инфекции и дисплазии эпителия шейки матки у сексуально активных девушек-подростков // Вопр. онкол. 1999. Т. 45. № 6. С. 623-626.
  5. Ершов Ф.И., Кубанова А.А., Пинегин Б.В. и др. Влияние терапии аллокином-альфа на течение рецидивов хронического генитального герпеса // Деловые партнеры. 2003. № 4 (40). С. 103-111.
  6. Ершов Ф.И., Ковчур П.И., Бахлаев И.Е. Применение аллокина-альфа в комплексной терапии папилломавирусной инфекции шейки матки // Акушерство и гинекология. 2009. № 2. С. 67-70.
  7. Киселев В.И., Ашрафян Л.А., Бударина С.О. Этиологическая роль вируса папилломы человека в развитии рака шейки матки: генетические и патогенетические механизмы, возможности терапии и профилактики // Гинекология. 2004. Т. 6. № 4. С. 174- 179.
  8. Прилепская В.Н., Роговская С.И., Бебнева Т.Н. и др. Лечение плоскоклеточных интраэпителиальных поражений шейки матки низкой степени. Акушерство и гинекология. 2009. № 2. С. 48-53:
  9. Серебряная Н.Б. Иммунные дисфункции при герпесвирусной инфекции: новые подходы к терапии // Мед. иммунол. 2005. Т. 7. № 2-3. С. 321-322.
  10. Федеральное руководство по использованию лекарственных средств. Вып. 5. М., 2004. Разд. 20.1.2.2.3.2.
  11. Черныш С.И. Аллокины (цитокиноподобные пептиды насекомых) как модуляторы иммунного ответа человека и других млекопитающих // Rus. J. Immunol. 2004. Vol. 9. S. 1. P. 36.
  12. American College of Obstetricians and Gynaecologists. COG Practice Bulletin jr° 99: Management of abnormal cervical cytology and histology // Obstet. Gynaecol. 2008, Dec. Vol. 112 (6). P. 1419-1444.
  13. Aubom K.J. Treatment of HPV-infection // Clin. Lab. Med. 2000. Vol. 20. № 2. P. 407-421.
  14. Bosch F.X., Manos M.M., Munoz N. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group // J. Nat. Cancer Inst. 1995. Vol. 87. P. 796-802.
  15. Bustin S.A. Quantification of mRNA using realtime reverse transcription PCR (RT-PCR): trends and problems // J. Mol. Endocrinol. 2002. Vol. 29. P. 23-39.
  16. Carcia-Hernandes E., Gonsales-Sanches J.L., An- drade-Manzano A. et al. Regression of papilloma high-grade lesion (CIN2 and CIN3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine // Cancer Gen. Ther. 2006. Vol. 13. P. 592- 597.
  17. Castle P.E., Sadorra M., Garcia F. Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology // J. Clin. Microbiol. 2006. Vol. 44 (11). P. 3915-3917.
  18. Chemysh S.I., Kim S.I., Bekker G. et al. Antiviral and antitumor peptides from insects // Proc. Nat. Acad. Sci. USA. 2002. Vol. 9. № 20. P. 12628- 12632.
  19. Dalstein V, Briolat J., Birembaut P. The epidemiology of genital human papillomavirus infections // Rev. Prat. 2006. Vol. 56 (17). P. 1877-1881.
  20. Einstein М.Н., Goldberg G.L. Human papillomavirus and cervical neoplasia // Cancer Invest. 2002. Vol. 20. P. 1080-1085.
  21. Ferlay J., Bray F., Pisani P., Parkin D.M., eds. Glo- bocan 2002. Cancer Incidence, Mortality and Prevalence Worldwide (I ARC Cancer Bases № 5. version 2.0), Lyon, IARC Press, 2004.
  22. Franco E.L., Rohan T.E., Villa L.L. Epidemiologic evidence and human papillovims infection as a necessary cause of cervical cancer// J. Nat. Cancer Inst. 1999. Vol. 91. P.506-511.
  23. Frazer H. Prevention of cervical cancer through papillomavirus vaccination//Nat. Rev. Immunol. 2004. Vol. 4. № 1. P. 46-54.
  24. IARC. Cervix cancer screening. IARC Handbooks of Cancer Prevention. Vol. 10. Lyon, International Agency for Research on Cancer, 2005.
  25. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. ѴЫ. 90. Human papillomaviruses. Lyon, France: International Agency for Research on Cancer, 2007.
  26. IARC. World Cancer Report 2008. Lyon, France: International Agency for Research on Cancer, 2008.
  27. Khleif S. Targeting human papillomavirus for cancer prevention and therapy. NCI, ASCO 2007. Educating book. P. 334-337.
  28. Khleif S.N. Molecular mechanisms of human papillomavirus-induced carcinogenesis: insights on potential targets for prevention. Orlando, ASCO 2005. Educational book P. 407-410.
  29. Kraus I., Molden T., Holm R. et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33 and 45 in the majority of cervical carcinomas // Am. Clin. Microbiol. 2006. Vol. 44. № 40. P. 1307-1310.
  30. Koutsky L.A. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection // N. Engl. J. Med. 1992. Vol. 327. P. 1272-1278.
  31. Kucera E., Sluitz G., Czervenka K. Is high risk HPV- infection associated with cervical intraepithelium neoplasia? // Eur. J. Obstet. Супесок Reprod. Biol. 2001. Vol. 100(1). P.72-76.
  32. Muderspach L., Wilczynski S., Roman L. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar interaepithelial neoplasia who are HPV 16 positive// Clin. Cancer Res. 2000. Vol. 6. P. 3406-3416.
  33. Munoz N.B.F. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer// Bull. Pan. Am. Health. Organ. 1996. Vol. 30. P.362-377.
  34. Munoz N., Hernandez-Suarez G., Mendez F. Persistence of HPV infection and risk of highgrade cervical intraepithelial neoplasia in a cohort of Colombian women // Br. J. Cancer. 2009. Vol. 100 (7). P. 1184-1190.
  35. Nagai Y., Maehama T., Asato T. et al. Persistence of HPV-infection after therapeutic conization for CIN3. Persistence of HPV-infection after therapeutic conization for CIN3 // Gynecol. Oncol. 2000. Vol. 79 , (2). P. 294-299.
  36. Oston A. Natural history of cervical intraepithelial neoplasia: a critical review // Int. J. Gynecol. Pathol. 1993. Vol. 12. P. 186-192.
  37. Plummer M., Franceschi S. Strategies for HPV prevention // Virus Res. 2002. Vol. 89. P. 285-293.
  38. Schiffman M.N. Epidemiology of cervical human papillovirus infection // Curr. Top. Microbiol. Immunol. 1994. Vol. 186. P.55-81.
  39. Snijders P.J., van den Brule A.J., Meijer C.J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity // Pathol. 2003. Vol. 201 (1). P. 1-6.
  40. Wheeler C.M., Hunt W.C., Schiffman M. Human papillomavirus genotypes and the cumulative 2- year risk of cervical precancer // J. Infect. Dis. 2006. Vol. 194 (9). P. 1291-1299.
  41. Winer R.L., KiviatN.B., Hughes J.P. Development and duration of human papillomavirus lesions, after initial infection//J. Infect. Dis. 2005. Vol. 191 (5). P. 731-738.
  42. Woodman C.B., Collins S., Winter H. Natural history of cervical Human papillomavirus infection in young women: a longitudinal cohort study // Lancet. 2001. Vol. 357. P. 1831-1836.
  43. Wojtowicz M., Hamilton J.M., Khong H. et al. Vaccination of cervical cancer patients with papillomavirus type 16 T6 and E7 peptides // Proc. Am. Soc. Clin. Oncol. 1999. Vol. 18. P. 441.
  44. Zelinski G.D., Rozendaal L., Voorhorst F.J et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3 // Gynecol. Oncol. 2003. Vol. 91. P. 67-73.

Views

Abstract - 177

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Kovchur P.I., Bahlaev I.E., Oleinik E.K., Oleinik V.M., Churov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.